
EU recommendation for Lilly’s soft tissue cancer drug
pharmafile | September 19, 2016 | News story | Sales and Marketing | CHMP, EMA, Eli Lilly, Lartruvo, soft tissue sarcoma
The Committee for Medicinal Products for Human Use (CHMP) has recommended Eli Lilly’s Lartruvo (olaratumab) for treatment of adults with the rare cancer, soft tissue sarcoma.
Olaratumab is a human IgG1 monoclonal antibody that is designed to disrupt the PDGF Receptor-α (platelet-derived growth factor receptor α) pathway on tumour cells and on cells in the tumour microenvironment.
The pharma firm’s drug is to be used in combination with doxorubicin for treatment of the illness for whom surgery or radiotherapy is not suitable, and who have not been previously treated with doxorubicin.
The FDA also fast-tracked review of the treatment in May.
The recommendation is based on data from Phase II of the JGDG study which showed a median improvement of 11.8 months in survival time of patients treated with a combination of doxorubicin plus Lartruvo compared to doxorubicin alone. The decision is thought to strongly encourage a marketing authorisation in the coming weeks.
Matt Fellows
Related Content

Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …

Lilly opens fourth US Gateway Labs site
Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …

Lilly’s drug for early Alzheimer’s shows promising results
Eli Lilly (Lilly) has announced positive new data from the long-term extension of its phase …






